Complete Local Tumor Regression with Antibody to Fibrin Fragment E

• Published in: The Journal of immunology (1950) Vol. 115; no. 4; pp. 976 - 981
• Main Authors: Schlager, Seymour I, Dray, Sheldon
• Format: Journal Article
• Language: English
• Published: United States Am Assoc Immnol 01.10.1975
• Subjects: Animals; Antibodies - administration & dosage; Carcinoma, Hepatocellular - immunology; Carcinoma, Hepatocellular - therapy; Counterimmunoelectrophoresis; Fibrin - immunology; Fibrin - isolation & purification; Guinea Pigs; Hypersensitivity, Delayed - immunology; Immune Sera - isolation & purification; Immunization Schedule; Immunodiffusion; Immunotherapy; Injections, Intradermal; Liver Neoplasms - immunology; Liver Neoplasms - therapy; Neoplasms, Experimental - immunology; Rabbits; Skin - pathology
• ISSN: 0022-1767; 1550-6606
• DOI: 10.4049/jimmunol.115.4.976

Rabbit antibody to fibrin fragment E (FFE) was used in an immunotherapy model for the treatment of the line-10 ascites variant of a diethylnitrosamine-induced hepatoma in strain 2 guinea pigs. When 0.75 or 1.0 mg of an IgG preparation containing anti-FFE antibody was injected s.c. 6 and 16 days after the injection of a uniformly lethal dose of line-10 tumor cells, complete regression of the i.d. growing tumor was observed in all 18 strain 2 guinea pigs treated. Thus, this therapy appears to be more effective than any BCG or other immunotherapeutic regimen thus far reported for this tumor. No significant anti-tumor effect was noted when normal rabbit IgG or smaller doses (0.25 or 0.50 mg) of the anti-FFE IgG preparation were used. The injection sites exhibited an inflammatory response for 7 to 10 days characterized by erythema and hemorrhage. Since all animals were treated after the metastatic progression of the tumor is known to frequently occur, the long-term tumor-free survival of these animals as well as their resistance to subsequent tumor challenge indicate that the anti-FFE antibody therapy led to systemic tumor immunity.